Literature DB >> 17283169

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

Mattias Carlsten1, Niklas K Björkström, Håkan Norell, Yenan Bryceson, Thorbald van Hall, Bettina C Baumann, Mikael Hanson, Kjell Schedvins, Rolf Kiessling, Hans-Gustaf Ljunggren, Karl-Johan Malmberg.   

Abstract

Although natural killer (NK) cells are well known for their ability to kill tumors, few studies have addressed the interactions between resting (nonactivated) NK cells and freshly isolated human tumors. Here, we show that human leukocyte antigen class I(low) tumor cells isolated directly from patients with advanced ovarian carcinoma trigger degranulation by resting allogeneic NK cells. This was paralleled by induction of granzyme B and caspase-6 activities in the tumor cells and significant tumor cell lysis. Ovarian carcinoma cells displayed ubiquitous expression of the DNAX accessory molecule-1 (DNAM-1) ligand PVR and sparse/heterogeneous expression of the NKG2D ligands MICA/MICB and ULBP1, ULBP2, and ULBP3. In line with the NK receptor ligand expression profiles, antibody-mediated blockade of activating receptor pathways revealed a dominant role for DNAM-1 and a complementary contribution of NKG2D signaling in tumor cell recognition. These results show that resting NK cells are capable of directly recognizing freshly isolated human tumor cells and identify ovarian carcinoma as a potential target for adoptive NK cell-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283169     DOI: 10.1158/0008-5472.CAN-06-2264

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

1.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Authors:  Melissa A Geller; David A Knorr; David A Hermanson; Lee Pribyl; Laura Bendzick; Valarie McCullar; Jeffrey S Miller; Dan S Kaufman
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

4.  Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.

Authors:  Zhenya Ni; David A Knorr; Laura Bendzick; Jeremy Allred; Dan S Kaufman
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

5.  Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

Authors:  Cyril Fauriat; Eric O Long; Hans-Gustaf Ljunggren; Yenan T Bryceson
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

6.  Vstm3 is a member of the CD28 family and an important modulator of T-cell function.

Authors:  Steven D Levin; David W Taft; Cameron S Brandt; Christoph Bucher; Edward D Howard; Eric M Chadwick; Janet Johnston; Angela Hammond; Kristen Bontadelli; Daniel Ardourel; LuAnn Hebb; Anitra Wolf; Thomas R Bukowski; Mark W Rixon; Joseph L Kuijper; Craig D Ostrander; James W West; Janine Bilsborough; Brian Fox; Zeren Gao; Wenfeng Xu; Fred Ramsdell; Bruce R Blazar; Katherine E Lewis
Journal:  Eur J Immunol       Date:  2011-03-18       Impact factor: 5.532

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

8.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

9.  MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.

Authors:  Jennifer A A Gubbels; Mildred Felder; Sachi Horibata; Jennifer A Belisle; Arvinder Kapur; Helen Holden; Sarah Petrie; Martine Migneault; Claudine Rancourt; Joseph P Connor; Manish S Patankar
Journal:  Mol Cancer       Date:  2010-01-20       Impact factor: 27.401

10.  Accelerated tumor growth in mice deficient in DNAM-1 receptor.

Authors:  Akiko Iguchi-Manaka; Hirayasu Kai; Yumi Yamashita; Kai Shibata; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Teruhito Yasui; Hitoshi Kikutani; Kazuko Shibuya; Akira Shibuya
Journal:  J Exp Med       Date:  2008-11-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.